BMN673

Catalog No. A11243

BMN-673是核酶聚（ADP-核糖）聚合酶（PARP）的口服生物利用抑制剂，无细胞试验中对PARP1的IC50为0.57 nM。它也是有效的PARP-2抑制剂，但不抑制PARG，对PTEN突变型高度敏感。具有潜在的抗肿瘤活性。

Product Citations

Subhajit Chatterjee, .et al. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping, J Cancer Res Clin Oncol, 2022, Dec;148(12):3521-3535 PMID: 35962813
Charles-André Philip, .et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors, BMC Cancer, 2017, 17: 638 PMID: 28886696

Technical details

Catalog Num	A11243
M. Wt	380.35
Formula	C19H14F2N6O
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	1207456-01-6
Synonyms	BMN-673, BMN 673
SMILES	CN1C(=NC=N1)[C@@H]2[C@H](N=C3C=C(C=C4C3=C2NNC4=O)F)C5=CC=C(C=C5)F

Biological Activity

Targets

PARP (Cell-free assay)
0.58 nM

Solubility *

In vitro	DMSO	Warmed: 38 mg/mL (99.9 mM)
	Water	Insoluble
	Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	26.29 mL	131.46 mL	262.92 mL
0.5 mM	5.26 mL	26.29 mL	52.58 mL
1 mM	2.63 mL	13.15 mL	26.29 mL
5 mM	0.53 mL	2.63 mL	5.26 mL

*The above data is based on the productmolecular weight 380.35. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.